Schwind CEO wins peace prize

Article

Rolf Schwind, CEO of Schwind Eye Tech Solutions, has been presented with the Gusi Peace Prize 2008 in a ceremony held on November 24th in Manila, the Philippines.

Rolf Schwind, CEO of Schwind Eye Tech Solutions GmbH, has been presented with the Gusi Peace Prize 2008 in a ceremony held on November 24th in Manila, the Philippines.

Mr Schwind's award was in recognition of his achievement in the field of industry and innovation, for the development of the Amaris laser. The innovations available with the Amaris - five-dimensional eye tracking and different energy levels for optimal ablation control - are not currently available on any other laser platform, which were the grounds for awarding this prize.

This is the eighth year the Gusi Peace Prize has been awarded. Fifteen winners were selected from almost 1500 nominees in the fields of medicine, chemistry, physics, journalism, politics, economics and art contributing to the advancement of peace and human rights.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.